Steady as she goes : Used to describe a ship sailing steady. It can be defined as being careful, steady, and being consistent.Contributing analyst to the iREIT+Hoya Capital investment group. The Dividend Collectuh is not a registered investment professional nor financial advisor and these articles should not be taken as financial advice. This is for educational purposes only and I encourage everyone to do their own due diligence. I'm a Navy veteran who enjoys dividend investing in quality blue-chip stocks, ...

Gilead Sciences, Inc. (GILD) entered into an exclusive option and license agreement with Tubulis, a Germany-based biotech company.The collaboration is aimed at discovering and developing an antibody-drug conjugate (ADC) against a solid tumor target.Gilead’s shares have risen 14.2% year to date against the industry's decline of 6.9%.Image Source: Zacks Investment ResearchMore on GILD’s Deal With TubulisThe single-asset focused collaboration, license and option agreement combines Tubulis’ differentiated ADC p ...

Conservative Income Portfolio targets the best value stocks with the highest margins of safety. The volatility of these investments is further lowered using the best priced options. Our Enhanced Equity Income Solutions Portfolio is designed to reduce volatility while generating 7-9% yields.Our previous takes on Agree Realty Corporation (NYSE: ADC ) have been on the neutral side, and we have only come away with a “hold” rating. The stockTrapping Value provides Covered Calls, and Preferred Stock Trader covers ...

With just a month left to the year, the S&P 500 is up 26% in 2024. Unless there's some major news over the next few weeks, the year will close out with a strong gain. Can it continue into 2025? There are indications that it can, such as an improving retail landscape and falling interest rates -- and there are indications that it can't, such as historically high valuations.What should investors do? One thing you can do when it's unclear what's going to happen next (which is basically all the time) is make su ...

Analyst’s Disclosure: I/we have a beneficial long position in the shares of ADC either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. While this article may sound like financial advice, please observe that the author is not a CFA or in any way licensed to give financial advice ...

Core Viewpoint - Defence Therapeutics Inc. is set to license its proprietary Accum® technology to pharmaceutical and biotech companies developing Antibody Drug Conjugates (ADCs), aiming to enhance ADC potency and reduce dosing requirements [3][4]. Group 1: Company Overview - Defence Therapeutics is a Canadian biopharmaceutical company focused on developing radiopharmaceuticals and ADC products, alongside novel immune-oncology vaccines [3][9]. - The company's Accum® technology is designed to improve the delivery and efficacy of biologics, particularly in oncology and immunotherapy applications, by overcoming endosomal entrapment [4][9]. Group 2: Business Model and Strategy - The licensing of Accum® technology is expected to generate immediate revenue while establishing the technology as an industry standard in ADC development [5]. - Defence plans to expand the applications of Accum® into other therapeutic areas, including radiopharmaceuticals, vaccines, and protein-based treatments, ensuring a sustainable revenue model that balances short-term profitability with long-term innovation [5]. Group 3: Financial Activities - The company recently closed a non-brokered private placement, issuing 50,000 units at a price of $0.50 per unit, raising gross proceeds of $25,000, which will be used to advance preclinical and clinical programs [6]. - An amendment was made to the terms of 1,497,780 Class A Common share purchase warrants, reducing the exercise price from $1.75 to $0.75 per share [7].

Core Insights - Realty Income (O) is a dominant player in the net lease sector with a market cap of $50 billion, significantly larger than its competitors [1] - Realty Income focuses on a diversified portfolio, owning over 15,400 properties, while Agree Realty owns around 2,250 properties [1][2] - Realty Income generates approximately 73% of its rents from retail properties, whereas Agree Realty is exclusively focused on retail assets [2] Company Growth and Strategy - The U.S. retail net lease market is estimated at $1.5 trillion, providing ample opportunities for growth, particularly for Agree Realty [3] - Realty Income's size presents challenges for growth, requiring substantial investment activity to expand its business [4] - In Q3 2024, Agree Realty acquired 66 properties, a significant number for them but relatively minor for Realty Income [4][5] Portfolio Diversification - Realty Income generates nearly 30% of its rents from "other" assets, including industrial properties and unique transactions like casinos and vineyards [6] - The company has expanded its portfolio to include European properties and is exploring the establishment of an asset management business [6] Dividend Performance - Agree Realty has shown a higher annualized dividend growth rate of around 6% over the past decade compared to Realty Income's 3% [7] - Realty Income currently offers a higher yield of 5.5% compared to Agree Realty's 4%, but for investors prioritizing growth, Agree Realty may be more appealing [8]

Group 1 - The investing group High Yield Landlord offers a free trial for potential investors to access their portfolio and top picks without any initial cost [1][2] - Jussi Askola, the leader of High Yield Landlord, is also the President of Leonberg Capital, which specializes in consulting on REIT investing for hedge funds and private equity firms [2] - The group provides features such as three distinct portfolios (core, retirement, international), buy/sell alerts, and a chat room for direct interaction with analysts [2] Group 2 - The article emphasizes that past performance does not guarantee future results, highlighting the inherent uncertainties in investment [4] - It is noted that the analysts involved may not be licensed or certified by any regulatory body, indicating a diverse range of backgrounds among contributors [4]

iREIT+HOYA Capital is the premier income-focused investing service on Seeking Alpha. Our focus is on income-producing asset classes that offer the opportunity for sustainable portfolio income , diversification , and inflation hedging . Get started with a Free Two-Week Trial and take a look at our top ideas across our exclusive income-focused portfolios.Warren Buffett has made headlines this year for selling a large amount of stock in holdings like Apple ( AAPL ) and Bank of America ( BAC ), and putting proc ...

Group 1 - Recent stock market volatility is attributed to the upcoming election, presenting a potential buying opportunity for long-term investors [1] Group 2 - The article emphasizes the importance of quality dividend-paying companies for building investment portfolios, particularly for lower and middle-class workers [2] - The author expresses a personal investment strategy focused on buy-and-hold approaches, aiming to supplement retirement income through dividends within the next 5-7 years [2]